Comparative Pharmacology
Head-to-head clinical analysis: DIMENHYDRINATE versus PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIMENHYDRINATE versus PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE.
DIMENHYDRINATE vs PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dimenhydrinate is a histamine H1 antagonist with central anticholinergic activity. It acts by blocking H1 receptors in the brain's vomiting center and inhibiting vestibular stimulation. It also has anticholinergic effects by binding to muscarinic receptors, reducing motion sickness.
Phenylephrine is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction; promethazine is a phenothiazine derivative that blocks histamine H1 receptors and has anticholinergic, antiemetic, and sedative effects.
50-100 mg orally or intramuscularly every 4-6 hours as needed; maximum 400 mg per day. For motion sickness, 50-100 mg 30 minutes before travel.
IV: 0.1-0.5 mg phenylephrine and 12.5-25 mg promethazine as a single dose.
None Documented
None Documented
Clinical Note
moderateDimenhydrinate + Venlafaxine
"The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Venlafaxine."
Clinical Note
moderateDimenhydrinate + Nefazodone
"The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Nefazodone."
Clinical Note
moderateDimenhydrinate + Stiripentol
"The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Stiripentol."
Clinical Note
moderateTerminal elimination half-life is 5-10 hours in adults, longer in elderly or hepatic impairment (up to 15 hours).
Phenylephrine: 2-3 hours (terminal). Promethazine: 10-14 hours (terminal in adults; prolonged in elderly and hepatic impairment).
Primarily renal, with 60-80% of the dose excreted unchanged in urine; minor biliary/fecal elimination accounts for <10%.
Phenylephrine: renal (80% as unchanged drug and sulfate conjugates). Promethazine: renal (70-80% as metabolites and unchanged drug), fecal (20-30%).
Category C
Category A/B
Antiemetic
Antihistamine / Antiemetic
Dimenhydrinate + Clomipramine
"The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Clomipramine."